T-Zell-Prolymphozytenleukämie

Die T-Zell-Prolymphozytenleukämie (T-PLL) ist eine sehr seltene, aggressiv verlaufende Leukämie reifer T-Zellen. Es imponiert in der Regel eine ausgeprägte Lymphozytose, häufig auch eine Splenomegalie. Zur Therapie wird Alemtuzumab in der Erstlinie empfohlen. Kurativ ist die allogene Stammzelltransplantation. Rezidive sind dennoch häufig.

Schlüsselwörter

T-PLL - Alemtuzumab - PTCL - T-Zell-Lymphom

• Literatur

• 1 Alaggio R, Amador C, Anagnostopoulos I. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720-1748
• 2 Cross MJ, Else M, Morilla R. et al. No Improvement in Survival for T-PLL Patients over the Last Two Decades. Blood 2019; 134: 1552-1552
• 3 Staber PB, Herling M, Bellido M. et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 2019; 134: 1132-1143
• 4 T-Zell Prolymphozytenleukämie – Onkopedia. Onkopedia.com. Accessed May 12, 2025 at: https://www.onkopedia.com/de/onkopedia/guidelines/t-zell-prolymphozytenleukaemie/@@guideline/html/index.html
• 5 Hu Z, Medeiros LJ, Fang L. et al. Prognostic significance of cytogenetic abnormalities in T‐cell prolymphocytic leukemia. American J Hematol 2017; 92: 441-447
• 6 Dearden CE, Khot A, Else M. et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 2011; 118: 5799-5802
• 7 Fachinformation: LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung. 2024.
• 8 Keating MJ, Cazin B, Coutré S. et al. Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. JCO 2002; 20: 205-213
• 9 Krishnan B, Else M, Tjonnfjord GE. et al. Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 2010; 149: 907-910
• 10 Szuszies CJ, Hasenkamp J, Jung W. et al. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy. Int J Hematol 2014; 100: 425-428
• 11 Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ. et al. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). Bone Marrow Transplant 2019; 54: 1391-1398
• 12 Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120: 538-551
• 13 Drozd-Sokolowska J, Gras L, Koster L. et al. Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. haematol 2024;
• 14 Sellner L, Brüggemann M, Schlitt M. et al. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplant 2017; 52: 544-551
• 15 Hopfinger G, Busch R, Pflug N. et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia. Cancer 2013; 119: 2258-2267
• 16 Mercieca J, Matutes E, Dearden C. et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. JCO 1994; 12: 2588-2593
• 17 Herbaux C, Genet P, Bouabdallah K. et al. Bendamustine is effective in T‐Cell prolymphocytic leukaemia. Br J Haematol 2015; 168: 916-919
• 18 Herling M, Dearden C, Zaja F. et al. Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Advances 2024; 8: 842-845